{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:55:41Z","timestamp":1790837741824,"version":"4.1.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>A gout flare is an episode of intense inflammation caused by the activation of NLR family pyrin domain containing 3 (NLRP3) inflammasome and production of interleukin (IL)-1\u03b2. This pathway is involved in pathogenesis of cardiovascular events and provides a plausible mechanism linking gout flares to cardiovascular diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Gout flares are associated with a transient increased risk of cardiovascular events (myocardial infarction, stroke, and cardiovascular death), venous thromboembolism, and tachyarrhythmia in the subsequent 30\u201360\u200a days \u2013 a finding comparable to that observed after other acute inflammatory states, such as influenza and pneumonia.<\/jats:p>\n                    <jats:p>Treat-to-target urate-lowering therapy lowered the risk of major adverse cardiovascular events in an emulated target trial. It also reduced systemic inflammation in observational studies. Additionally, gout flare prophylaxis with colchicine was associated with lower rates of major adverse cardiovascular events in a nationwide cohort study without evidence of residual confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Patients with gout are at a high risk of cardiovascular diseases. Recent data suggest that patients presenting with gout flares warrant heightened vigilance for cardiovascular events, venous thromboembolism, and tachyarrhythmia\u00a0over the following 30\u201360\u200adays. Treating gout to the target serum urate level could prevent cardiovascular events and renal function decline. Gout flare prophylaxis with colchicine may have a similar effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001183","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:02:41Z","timestamp":1787144561000},"page":"412-419","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Systemic effects of gout flares beyond the joints"],"prefix":"10.1097","volume":"38","author":[{"given":"Edoardo","family":"Cipolletta","sequence":"first","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, UK"},{"name":"Department of Internal Medicine, Marche University Hospital, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[{"name":"NIHR Birmingham Biomedical Research Centre, Institute of Translational Medicine, Birmingham"},{"name":"Keele Cardiovascular Research Group, Keele University, Keele, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2021-221989","article-title":"Has the gout epidemic peaked in the UK? A nationwide cohort study using data from the Clinical Practice Research Datalink, from 1997 to across the COVID-19 pandemic in 2021","volume":"81","author":"Abhishek","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007\u20132016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","article-title":"Global, regional, and national burden of gout, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"6","author":"Cross","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1093\/rheumatology\/keab335","article-title":"The inflammatory role of silent urate crystal deposition in intercritical gout","volume":"60","author":"Diaz-Torne","year":"2021","journal-title":"Rheumatology"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"keaf680","DOI":"10.1093\/rheumatology\/keaf680","article-title":"Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy","author":"Wheeler","year":"2025","journal-title":"Rheumatology"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13075-022-02772-3","article-title":"One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study","volume":"24","author":"Uhlig","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1093\/rheumatology\/kead124","article-title":"Course and predictors of work productivity in gout \u2014 results from the NOR-Gout longitudinal 2-year treat-to-target study","volume":"62","author":"Uhlig","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.semarthrit.2020.06.001","article-title":"The experience of a gout flare: a meta-synthesis of qualitative studies","volume":"50","author":"Stewart","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/acr.22324","article-title":"Using natural language processing and machine learning to identify gout flares from electronic clinical notes","volume":"66","author":"Zheng","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pds.4044","article-title":"Validation of claims-based algorithms for gout flares","volume":"25","author":"MacFarlane","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"e5684","DOI":"10.1002\/pds.5684","article-title":"Improving the accuracy of automated gout flare ascertainment using natural language processing of electronic health records and linked Medicare claims data","volume":"33","author":"Yoshida","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/jama.2023.26640","article-title":"Serum urate and recurrent gout","volume":"331","author":"McCormick","year":"2024","journal-title":"JAMA"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.42480","article-title":"Risk of venous thromboembolism with gout flares","volume":"75","author":"Cipolletta","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2665-9913(24)00248-0","article-title":"Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data","volume":"7","author":"Cipolletta","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","article-title":"Frequency and risk factors of gout flares in a large population-based cohort of incident gout","volume":"50","author":"Rothenbacher","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"R224","DOI":"10.1186\/ar4425","article-title":"Veterans Affairs databases are accurate for gout-related healthcare utilization: a validation study","volume":"15","author":"Singh","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1016\/S2665-9913(23)00338-7","article-title":"Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls","volume":"6","author":"Ferguson","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/rheumatology\/kez398","article-title":"Trends of venous thromboembolism risk before and after diagnosis of gout: a general population-based study","volume":"59","author":"Li","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/rheumatology\/kev418","article-title":"Impact of gout on the risk of atrial fibrillation","volume":"55","author":"Kuo","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/art.22014","article-title":"Gout and the risk of acute myocardial infarction","volume":"54","author":"Krishnan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/rheumatology\/kes169","article-title":"Risk of myocardial infarction among patients with gout: a nationwide population-based study","volume":"52","author":"Kuo","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"j2376","DOI":"10.1136\/bmj.j2376","article-title":"Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies","volume":"357","author":"Li","year":"2017","journal-title":"BMJ"},{"key":"R27-20261001","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/art.41779","article-title":"Assessing the causal relationships between insulin resistance and hyperuricemia and gout using bidirectional mendelian randomization","volume":"73","author":"McCormick","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejim.2023.06.013","article-title":"How does current disease activity in rheumatoid arthritis affect the short-term risk of acute coronary syndrome? A clinical register based study from Sweden and Norway","volume":"115","author":"Delcoigne","year":"2023","journal-title":"Eur J Intern Med"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"e56944","DOI":"10.1371\/journal.pone.0056944","article-title":"Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death \u2013 a Danish Nationwide Cohort Study","volume":"8","author":"Kristensen","year":"2013","journal-title":"PLoS One"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"e097754","DOI":"10.1136\/bmjopen-2024-097754","article-title":"Risk of myocardial infarction and stroke following microbiologically confirmed urinary tract infection: a self-controlled case series study using linked electronic health data","volume":"15","author":"Reeve","year":"2025","journal-title":"BMJ Open"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1702090","article-title":"Acute myocardial infarction after laboratory-confirmed influenza infection","volume":"378","author":"Kwong","year":"2018","journal-title":"N Engl J Med"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.amjmed.2010.11.014","article-title":"Incidence of cardiovascular events after hospital admission for pneumonia","volume":"124","author":"Perry","year":"2011","journal-title":"Am J Med"},{"key":"R34-20261001","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/acr2.11540","article-title":"Risk of major adverse cardiovascular event following incident hospitalization for acute gout: a Western Australian Population-Level Linked Data Study","volume":"5","author":"Lopez","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019\u200aESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/art.42986","article-title":"Short-term risk of cardiovascular events in people newly diagnosed with gout","volume":"77","author":"Cipolletta","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R37-20261001","doi-asserted-by":"crossref","first-page":"keag370","DOI":"10.1093\/rheumatology\/keag370","article-title":"Annual gout flare frequency as a marker of sustained cardiovascular risk: a clinical threshold for risk stratification","volume":"65","author":"Tung","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.lanprc.2026.100170","article-title":"Association between tachyarrhythmia and gout flare in people with gout in England and Sweden: nested case-control studies and self-controlled case-series analyses","volume":"2","author":"Cipolletta","year":"2026","journal-title":"Lancet Primary Care"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3899\/jrheum.190974","article-title":"Epidemiology of depression and anxiety in gout: a systematic review and metaanalysis","volume":"48","author":"Howren","year":"2021","journal-title":"J Rheumatol"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12882-026-04904-2","article-title":"Gout flare burden as a marker of chronic kidney disease risk","volume":"27","author":"Wang","year":"2026","journal-title":"BMC Nephrol"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"R42-20261001","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1093\/cvr\/cvab337","article-title":"Interleukin-1\u03b2 suppression dampens inflammatory leucocyte production and uptake in atherosclerosis","volume":"118","author":"Hettwer","year":"2022","journal-title":"Cardiovasc Res"},{"key":"R43-20261001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tcm.2007.09.001","article-title":"Metalloproteinases and vulnerable atherosclerotic plaques","volume":"17","author":"Newby","year":"2007","journal-title":"Trends Cardiovasc Med"},{"key":"R44-20261001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJMoa012295","article-title":"Widespread coronary inflammation in unstable angina","volume":"347","author":"Buffon","year":"2002","journal-title":"N Engl J Med"},{"key":"R45-20261001","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"R46-20261001","doi-asserted-by":"crossref","first-page":"H877","DOI":"10.1152\/ajpheart.00223.2019","article-title":"Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling","volume":"317","author":"Suetomi","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R47-20261001","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"key":"R48-20261001","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41569-021-00520-9","article-title":"Electroimmunology and cardiac arrhythmia","volume":"18","author":"Grune","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"R49-20261001","doi-asserted-by":"crossref","first-page":"387","DOI":"10.31083\/j.rcm2312387","article-title":"Colchicine for prevention of post-cardiac surgery and post-pulmonary vein isolation atrial fibrillation: a meta-analysis","volume":"23","author":"Wang","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"R50-20261001","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"R51-20261001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R52-20261001","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"R53-20261001","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"R54-20261001","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"R55-20261001","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/cvr\/cvae191","article-title":"Optical coherence tomography assessment of the impact of colchicine on nonculprit coronary plaque composition after myocardial infarction","volume":"121","author":"Psaltis","year":"2025","journal-title":"Cardiovasc Res"},{"key":"R56-20261001","first-page":"CD014808","article-title":"Colchicine for the secondary prevention of cardiovascular events","volume":"11","author":"Ebrahimi","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"R57-20261001","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/jamainternmed.2025.7453","article-title":"Treat-to-target urate-lowering treatment and cardiovascular outcomes in patients with gout","volume":"186","author":"Cipolletta","year":"2026","journal-title":"JAMA Intern Med"},{"key":"R58-20261001","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/EDE.0000000000001608","article-title":"Comparative safety of gout treatment strategies on cardiovascular outcomes using observational data: clone-censor-weight target trial emulation approach","volume":"34","author":"Yoshida","year":"2023","journal-title":"Epidemiology"},{"key":"R59-20261001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ard.2025.05.028","article-title":"OP0005 Cardiovascular outcomes of treat-to-target versus fire-and-forget urate-lowering treatment in gout: emulated target trial studies using linked English and Swedish primary care, hospitalisation and mortality data","volume":"84","author":"Cipolletta","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R60-20261001","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamainternmed.2024.6212","article-title":"Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease","volume":"185","author":"Wang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"R61-20261001","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/art.43259","article-title":"Comparative cardiovascular safety of nonsteroidal anti-inflammatory drug versus colchicine use when initiating urate-lowering therapy among patients with gout: target trial emulations","volume":"77","author":"Yokose","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R62-20261001","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/1756-185X.14825","article-title":"Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database","volume":"26","author":"So","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"R63-20261001","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three Phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"key":"R64-20261001","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/ard-2023-224731","article-title":"Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A noninferiority randomised double-blind placebo-controlled trial","volume":"82","author":"Stamp","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:02:55Z","timestamp":1790834575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001183","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}